Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate ...

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Investors fled the company's stock in 2024 as a slow US launch of Leqembi, the Alzheimer's disease drug it sells with Japan's ...

In the fourth quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.

The long-awaited decision will come as a blow to thousands of MS sufferers who have been pinning their hopes on obtaining the drug. In November, the final appraisal on the use of the drug was ...

There aren’t any reports of these two medications interacting with each other. People with MS often take ibuprofen or another nonsteroidal anti-inflammatory drug (NSAID) to manage muscle pain ...

(CNN) – The U.S. Food and Drug Administration approved the first new type of pain medication in more than two decades, and it’s not an opioid. The drug is suzetrigine under the brand name ...

(CNN) – The U.S. Food and Drug Administration approved the first new type of pain medication in more than two decades, and it’s not an opioid. The drug is suzetrigine under the brand name Journavx. It ...

The following day, the three suspects had their arraignment on various felonies and misdemeanor counts for allegedly possessing, delivering and selling illegal drugs. In court documents, police said ...